Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.06USD
15 Dec 2017
Change (% chg)

$0.01 (+0.95%)
Prev Close
$1.05
Open
$1.06
Day's High
$1.08
Day's Low
$1.06
Volume
56,947
Avg. Vol
55,565
52-wk High
$1.38
52-wk Low
$0.80

Chart for

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

Dec 04 2017

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

Nov 21 2017

BRIEF-BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

* BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

Oct 18 2017

BRIEF-BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

* BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration Source text for Eikon: Further company coverage:

Sep 26 2017

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization

Aug 21 2017

BRIEF-Biolinerx Q2 ‍loss per share $0.05​

* Qtrly ‍loss per share $0.05​ Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Biolinerx announces additional investment from BVF Partners L.P.

* BiolineRx announces additional investment from BVF partners L.P.

Jul 26 2017

BVF raises stake in biopharma firm BioLineRx to 24.9 pct

* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.

Jul 26 2017

Earnings vs. Estimates